UroGen Pharma Ltd. (URGN)
36.61
+0.03
(+0.08%)
USD |
NASDAQ |
Oct 15, 16:00
36.57
-0.04
(-0.11%)
After-Hours: 20:00
UroGen Pharma Research and Development Expense (Quarterly) : 17.34M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 17.34M |
| March 31, 2026 | 15.60M |
| December 31, 2025 | 14.31M |
| September 30, 2025 | 14.01M |
| June 30, 2025 | 18.91M |
| March 31, 2025 | 19.87M |
| December 31, 2024 | 14.89M |
| September 30, 2024 | 11.36M |
| June 30, 2024 | 15.40M |
| March 31, 2024 | 15.49M |
| December 31, 2023 | 11.30M |
| September 30, 2023 | 10.23M |
| June 30, 2023 | 11.58M |
| March 31, 2023 | 12.50M |
| December 31, 2022 | 14.48M |
| September 30, 2022 | 13.09M |
| June 30, 2022 | 12.64M |
| March 31, 2022 | 12.70M |
| December 31, 2021 | 13.08M |
| Date | Value |
|---|---|
| September 30, 2021 | 11.92M |
| June 30, 2021 | 12.12M |
| March 31, 2021 | 10.51M |
| December 31, 2020 | 11.79M |
| September 30, 2020 | 9.713M |
| June 30, 2020 | 7.631M |
| March 31, 2020 | 16.13M |
| December 31, 2019 | 20.09M |
| September 30, 2019 | 9.481M |
| June 30, 2019 | 9.996M |
| March 31, 2019 | 9.726M |
| December 31, 2018 | 11.46M |
| September 30, 2018 | 9.574M |
| June 30, 2018 | 8.273M |
| March 31, 2018 | 7.622M |
| December 31, 2017 | 6.761M |
| September 30, 2017 | 5.621M |
| June 30, 2017 | 3.651M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Xencor, Inc. | 71.90M |
| MeiraGTx Holdings Plc | 57.83M |
| Insmed, Inc. | 210.03M |
| Ironwood Pharmaceuticals, Inc. | 21.96M |
| Viking Therapeutics, Inc. | 115.75M |